Taking what we know from the SLE studies, we can extrapolate that the adverse effects of estrogen via ER-α in the setting of CVD may be due to an exacerbation of the immune response which is a known critical player in multiple cardiovascular pathologies. The gene discussed is ESR1; the disease is systemic lupus erythematosus.